Clinical Trial Update: A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of olaparib and pembrolizumab in triple-negative breast cancer and hormone receptor-positive, HER2-negative breast canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING